Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VBPZG
ADC Name
FS001-VH4-VL3-VC-MMAE
Synonyms
FS001-VH4-VL3-VC-MMAE
   Click to Show/Hide
Organization
FORESEEN TECHNOLOGY (BEIJING) CO., LTD.
Drug Status
Investigative
Drug-to-Antibody Ratio
3.8
Structure
Antibody Name
FS001-huVH4-huVL3
  Antibody Info 
Antigen Name
Glypican-3 (GPC3)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.17
nM
CVCL_0336
Adult hepatocellular carcinoma
Half Maximal inhibitory Concentration (lC50) 
0.63
nM
CVCL_0027
Hepatoblastoma
Half Maximal inhibitory Concentration (lC50) 
> 207
nM
CVCL_0213
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.17 nM Positive GPC3 expression (GPC3+++/++)
Method Description
HuH7 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
In Vitro Model Adult hepatocellular carcinoma HuH7 cells CVCL_0336
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.63 nM Positive GPC3 expression (GPC3+++/++)
Method Description
HepG2 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
In Vitro Model Hepatoblastoma HepG2 cells CVCL_0027
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 207 nM Negative GPC3expression (GPC3-)
Method Description
CHO 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
In Vitro Model Normal CHO cells CVCL_0213
References
Ref 1 Monoclonal antibodies targeting GPC3 and antibody-drug conjugates comprising the antibodies